Clinical trial
Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Surface Antigen Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.
NCT00562237 is registered in ClinicalTrials.gov with Solvay Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Surface Antigen Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.
- Lead sponsor
- Solvay Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- July 31, 2007
- Completion date
- September 30, 2008
- Enrollment
- 400 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
healthy subjects